{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:36:22Z","timestamp":1791999382016,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psilocybin is the most researched classic psychedelic for Treatment-Resistant Depression (TRD). While optimizing set and setting are considered essential for efficacy and safety, patient perspectives on these aspects have rarely been investigated. To address this knowledge gap, the current paper explored the experiences of 11 TRD patients (8 women, 3 men) participating in a double-blind randomized clinical trial with a single session of oral (1, 10 or 25\u00a0mg) psilocybin treatment. After qualitative analysis, three major themes were identified: (1) challenges with trust-building and expectation management; (2) navigating the experience; and (3) the need for a more comprehensive treatment. Subthemes of the first theme include a general distrust in mental healthcare, trust in study therapists, limited time for preparation, and managing expectations. The second theme included the following subthemes: trusting to surrender, profound and overwhelming experiences, and music as a guide. The third theme addressed a desire for multiple psilocybin sessions, and challenges with sensemaking. Patients\u2019 perspectives provided important insights into potential optimization of psilocybin treatment of TRD, including individualized preparation, investment in trust-building, offering additional psilocybin sessions, providing access to sustained (psycho)therapy with trusted therapists, and personalizing treatment approaches, which may also enhance real-world adaption of these treatments.<\/jats:p>","DOI":"10.1038\/s41598-024-53188-9","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T11:03:41Z","timestamp":1707131021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-4610","authenticated-orcid":false,"given":"Joost J.","family":"Breeksema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Niemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Krediet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Karsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0579-4404","authenticated-orcid":false,"given":"Eric","family":"Vermetten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0760-9866","authenticated-orcid":false,"given":"Robert","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"issue":"11","key":"53188_CR1","doi-asserted-by":"publisher","first-page":"e1001547","DOI":"10.1371\/journal.pmed.1001547","volume":"10","author":"AJ Ferrari","year":"2013","unstructured":"Ferrari, A. J. et al. Burden of depressive disorders by country, sex, age, and year: Findings from the Global Burden of Disease Study 2010. PLoS Med. 10(11), e1001547 (2013).","journal-title":"PLoS Med."},{"issue":"6","key":"53188_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2018-024886","volume":"9","author":"K Munkholm","year":"2019","unstructured":"Munkholm, K., Paludan-M\u00fcller, A. S. & Boesen, K. Considering the methodological limitations in the evidence base of antidepressants for depression: A reanalysis of a network meta-analysis. BMJ Open 9(6), 1\u20139 (2019).","journal-title":"BMJ Open"},{"issue":"November","key":"53188_CR3","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"16311","author":"JA Rush","year":"2006","unstructured":"Rush, J. A. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatry 16311(November), 1905\u20131917 (2006).","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"53188_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/14740338.2022.2047928","volume":"21","author":"A Bahji","year":"2022","unstructured":"Bahji, A., Zarate, C. A. & Vazquez, G. H. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opin. Drug Saf. 21(6), 853\u2013866 (2022).","journal-title":"Expert Opin. Drug Saf."},{"issue":"322","key":"53188_CR5","first-page":"194","volume":"2023","author":"K Ko","year":"2022","unstructured":"Ko, K., Kopra, E. I., Cleare, A. J. & Rucker, J. J. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. J. Affect. Disord. 2023(322), 194\u2013204 (2022).","journal-title":"J. Affect. Disord."},{"issue":"10","key":"53188_CR6","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza, D. C. et al. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 47(10), 1854\u20131862 (2022).","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"53188_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/da.22968","volume":"37","author":"BN Gaynes","year":"2020","unstructured":"Gaynes, B. N. et al. Defining treatment-resistant depression. Depress. Anxiety 37(2), 134\u2013145 (2020).","journal-title":"Depress. Anxiety"},{"issue":"18","key":"53188_CR8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387(18), 1637\u20131648 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"53188_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA 330(9), 843\u2013853 (2023).","journal-title":"JAMA"},{"issue":"7","key":"53188_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry 3(7), 619\u2013627 (2016).","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"53188_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2020","unstructured":"Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78(5), 481\u2013489 (2020).","journal-title":"JAMA Psychiatry"},{"issue":"15","key":"53188_CR12","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384(15), 1402\u20131411 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"February","key":"53188_CR13","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R von Rotz","year":"2023","unstructured":"von Rotz, R. et al. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine 56(February), 101809 (2023).","journal-title":"eClinicalMedicine"},{"issue":"269881123115485","key":"53188_CR14","first-page":"1","volume":"20","author":"J Sloshower","year":"2023","unstructured":"Sloshower, J. et al. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. J. Psychopharmacol. 20(2698811231154852), 1\u20139 (2023).","journal-title":"J. Psychopharmacol."},{"key":"53188_CR15","unstructured":"Brooks M. FDA Grants Psilocybin Second Breakthrough Therapy Designation for Resistant Depression. Medscape. 2019 [cited 2020 Jun 3]. https:\/\/www.medscape.com\/viewarticle\/921789."},{"issue":"2","key":"53188_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00213-020-05719-1","volume":"238","author":"NL Galv\u00e3o-Coelho","year":"2021","unstructured":"Galv\u00e3o-Coelho, N. L. et al. Classic serotonergic psychedelics for mood and depressive symptoms: A meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berlin) 238(2), 341\u2013354 (2021).","journal-title":"Psychopharmacology (Berlin)"},{"issue":"2","key":"53188_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology (Berlin) 235(2), 399\u2013408 (2018).","journal-title":"Psychopharmacology (Berlin)"},{"issue":"2","key":"53188_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan, N. et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J. Psychopharmacol. 36(2), 151\u2013158 (2022).","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"53188_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40263-020-00748-y","volume":"34","author":"JJ Breeksema","year":"2020","unstructured":"Breeksema, J. J. et al. Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs 34(9), 925\u2013946 (2020).","journal-title":"CNS Drugs"},{"issue":"January","key":"53188_CR20","first-page":"1","volume":"2","author":"M Crowe","year":"2023","unstructured":"Crowe, M., Manuel, J., Carlyle, D. & Lacey, C. Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. Int. J. Ment. Health Nurs. 2(January), 1\u201313 (2023).","journal-title":"Int. J. Ment. Health Nurs."},{"issue":"5","key":"53188_CR21","first-page":"520","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts, R., Day, C., Krzanowski, J., Nutt, D. & Carhart-Harris, R. Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J. Hum. Psychol. 57(5), 520\u2013564 (2017).","journal-title":"J. Hum. Psychol."},{"issue":"5","key":"53188_CR22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00213-018-4886-8","volume":"235","author":"M Kaelen","year":"2018","unstructured":"Kaelen, M. et al. The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology (Berlin) 235(5), 1623 (2018).","journal-title":"Psychopharmacology (Berlin)"},{"issue":"7","key":"53188_CR23","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. et al. Psychedelics and the essential importance of context. J. Psychopharmacol. 32(7), 725\u2013731 (2018).","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"53188_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson, M., Richards, W. & Griffths, R. Human hallucinogen research: guidelines for safety. J. Psychopharmacol. 22(6), 603\u2013620 (2008).","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"53188_CR25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn, I. Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J. Psychopharmacol. 30(12), 1259\u20131267 (2016).","journal-title":"J. Psychopharmacol."},{"key":"53188_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00005053-196312000-00007","volume":"137","author":"T Leary","year":"1963","unstructured":"Leary, T., Lithwin, G. H. & Metzner, R. Reactions to psilocybin administed in a supportive environment. J.Nerv. Ment. Dis. 137, 561\u2013573 (1963).","journal-title":"J.Nerv. Ment. Dis."},{"key":"53188_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2050324516683325","volume":"3","author":"I Hartogsohn","year":"2017","unstructured":"Hartogsohn, I. Constructing drug effects: A history of set and setting. Drug Sci. Policy Law 3, 1\u201317 (2017).","journal-title":"Drug Sci. Policy Law"},{"issue":"1","key":"53188_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-018-1625-y","volume":"18","author":"R Mago","year":"2018","unstructured":"Mago, R., Fagiolini, A., Weiller, E. & Weiss, C. Understanding the emotions of patients with inadequate response to antidepressant treatments: Results of an international online survey in patients with major depressive disorder. BMC Psychiatry 18(1), 1\u20139 (2018).","journal-title":"BMC Psychiatry"},{"issue":"1","key":"53188_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40359-019-0347-3","volume":"7","author":"P Crits-Christoph","year":"2019","unstructured":"Crits-Christoph, P., Rieger, A., Gaines, A. & Gibbons, M. B. C. Trust and respect in the patient-clinician relationship: Preliminary development of a new scale. BMC Psychol. 7(1), 1\u20138 (2019).","journal-title":"BMC Psychol."},{"issue":"3","key":"53188_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1037\/h0085885","volume":"16","author":"ES Bordin","year":"1979","unstructured":"Bordin, E. S. The generalizability of the psychoanalytic concept of the working alliance. Psychother. Theory Res. Pract. 16(3), 252\u2013260 (1979).","journal-title":"Psychother. Theory Res. Pract."},{"key":"53188_CR31","first-page":"1","volume":"00","author":"J Phelps","year":"2017","unstructured":"Phelps, J. Developing guidelines and competencies for the training of psychedelic therapists. J. Hum. Psychol. 00, 1\u201338 (2017).","journal-title":"J. Hum. Psychol."},{"key":"53188_CR32","first-page":"1","volume":"2","author":"AD Penn","year":"2021","unstructured":"Penn, A. D., Phelps, J., Rosa, W. E. & Watson, J. Psychedelic-assisted psychotherapy practices and human caring science: toward a care-informed model of treatment. J. Hum. Psychol. 2, 1\u201326 (2021).","journal-title":"J. Hum. Psychol."},{"key":"53188_CR33","first-page":"1","volume":"89","author":"S Thal","year":"2022","unstructured":"Thal, S., Engel, L. B. & Bright, S. J. Presence, trust, and empathy: preferred characteristics of psychedelic carers. J. Hum. Psychol. 89, 1\u201324 (2022).","journal-title":"J. Hum. Psychol."},{"issue":"7","key":"53188_CR34","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/0269881118780612","volume":"32","author":"T Noorani","year":"2018","unstructured":"Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R. & Johnson, M. W. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. J. Psychopharmacol. 32(7), 756\u2013769 (2018).","journal-title":"J. Psychopharmacol."},{"key":"53188_CR35","unstructured":"Grof, S. LSD Psychotherapy. Third. Sarasota, Florida: Multidisciplinary Association for Psychedelic Studies; 2001."},{"issue":"948115","key":"53188_CR36","first-page":"01","volume":"13","author":"JJ Breeksema","year":"2022","unstructured":"Breeksema, J. J., Niemeijer, A., Kuin, B., van den Brink, W. & Vermetten, E. Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: a qualitative study. Front. Psychiatry 13(948115), 01\u201316 (2022).","journal-title":"Front. Psychiatry"},{"issue":"11","key":"53188_CR37","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00213-019-05279-z","volume":"236","author":"SL Russ","year":"2019","unstructured":"Russ, S. L., Carhart-Harris, R. L., Maruyama, G. & Elliott, M. S. Replication and extension of a model predicting response to psilocybin. Psychopharmacology (Berlin) 236(11), 3221\u20133230 (2019).","journal-title":"Psychopharmacology (Berlin)"},{"issue":"NOV","key":"53188_CR38","first-page":"1","volume":"9","author":"ECHM Haijen","year":"2018","unstructured":"Haijen, E. C. H. M. et al. Predicting responses to psychedelics: A prospective study. Front Pharmacol. 9(NOV), 1\u201320 (2018).","journal-title":"Front Pharmacol."},{"issue":"2","key":"53188_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030800","volume":"7","author":"E Studerus","year":"2012","unstructured":"Studerus, E., Gamma, A., Kometer, M. & Vollenweider, F. X. Prediction of psilocybin response in healthy volunteers. PLoS ONE 7(2), e30800 (2012).","journal-title":"PLoS ONE"},{"issue":"2","key":"53188_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","volume":"4","author":"JS Aday","year":"2021","unstructured":"Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K. & Davoli, C. C. Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects. ACS Pharmacol. Transl. Sci. 4(2), 424\u2013435 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"53188_CR41","first-page":"1","volume":"371","author":"CA Nelson","year":"2020","unstructured":"Nelson, C. A. et al. Adversity in childhood is linked to mental and physical health throughout life. BMJ 371, 1\u20139 (2020).","journal-title":"BMJ"},{"issue":"1","key":"53188_CR42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jad.2013.06.037","volume":"152\u2013154","author":"C Tunnard","year":"2014","unstructured":"Tunnard, C. et al. The impact of childhood adversity on suicidality and clinical course in treatment-resistant depression. J. Affect. Disord. 152\u2013154(1), 122\u2013130 (2014).","journal-title":"J. Affect. Disord."},{"issue":"4","key":"53188_CR43","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1371\/journal.pone.0250148","volume":"16","author":"A Yrondi","year":"2021","unstructured":"Yrondi, A. et al. Relationship between childhood physical abuse and clinical severity of treatment-resistant depression in a geriatric population. PLoS ONE 16(4), 5487 (2021).","journal-title":"PLoS ONE"},{"issue":"3","key":"53188_CR44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1600-0447.2011.01828.x","volume":"126","author":"JGFM Hovens","year":"2012","unstructured":"Hovens, J. G. F. M. et al. Impact of childhood life events and trauma on the course of depressive and anxiety disorders. Acta Psychiatr. Scand. 126(3), 198\u2013207 (2012).","journal-title":"Acta Psychiatr. Scand."},{"issue":"June","key":"53188_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2020.104840","volume":"121","author":"S Zheng","year":"2020","unstructured":"Zheng, S. et al. Oxytocin receptor gene (OXTR) and CHILDHOOD ADVERSITY INFLUENCE TRUst. Psychoneuroendocrinology 121(June), 104840 (2020).","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"53188_CR46","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1037\/a0020327","volume":"136","author":"R Kotov","year":"2010","unstructured":"Kotov, R., Gamez, W., Schmidt, F. & Watson, D. Linking, \u201cBig\u201d personality traits to anxiety, depressive, and substance use disorders: A meta-analysis. Psychol. Bull. 136(5), 768\u2013821 (2010).","journal-title":"Psychol. Bull."},{"key":"53188_CR47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jad.2021.03.061","volume":"288","author":"K Lyon","year":"2021","unstructured":"Lyon, K., Elliott, R., Ware, K., Juhasz, G. & Brown, L. Associations between facets and aspects of big five personality and affective disorders: a systematic review and best evidence synthesis. J. Affect. Disord. 288, 175\u2013188 (2021).","journal-title":"J. Affect. Disord."},{"key":"53188_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","volume":"117","author":"FS Barrett","year":"2017","unstructured":"Barrett, F. S., Johnson, M. W. & Griffiths, R. R. Neuroticism is associated with challenging experiences with psilocybin mushrooms. Pers. Ind. Differ. 117, 155\u2013160 (2017).","journal-title":"Pers. Ind. Differ."},{"key":"53188_CR49","volume-title":"Sacred Knowledge: Psychedelics and Religious Experiences","author":"WA Richards","year":"2016","unstructured":"Richards, W. A. Sacred Knowledge: Psychedelics and Religious Experiences (Columbia University Press, 2016)."},{"key":"53188_CR50","unstructured":"Noorani T. The Pollan Effect: Psychedelic Research between World and Word [Internet]. Society for Cultural Anthropology. 2020 [cited 2023 Apr 4]. https:\/\/culanth.org\/fieldsights\/the-pollan-effect-psychedelic-research-between-world-and-word."},{"issue":"10","key":"53188_CR51","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","volume":"239","author":"M Butler","year":"2022","unstructured":"Butler, M., Jelen, L. & Rucker, J. Expectancy in placebo-controlled trials of psychedelics: If so, so what?. Psychopharmacology (Berlin) 239(10), 3047\u20133055 (2022).","journal-title":"Psychopharmacology (Berlin)"},{"key":"53188_CR52","doi-asserted-by":"crossref","unstructured":"Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berlin) 2022;(April).","DOI":"10.31234\/osf.io\/nrb3t"},{"issue":"9","key":"53188_CR53","first-page":"863","volume":"385","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R., Blemings, A. & Nutt, D. J. Psilocybin for depression. Authors reply. New 385(9), 863\u2013864 (2021).","journal-title":"New"},{"issue":"4","key":"53188_CR54","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","volume":"111","author":"AM Becker","year":"2022","unstructured":"Becker, A. M. et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double- \u00ad blind, placebo- \u00ad controlled, crossover study in healthy subjects. Clin Pharmacol Ther. 111(4), 886\u2013895 (2022).","journal-title":"Clin Pharmacol Ther."},{"key":"53188_CR55","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","volume":"48","author":"GM Goodwin","year":"2023","unstructured":"Goodwin, G. M. et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 48, 1492\u20131499 (2023).","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"53188_CR56","first-page":"488","volume":"57","author":"TC Swift","year":"2017","unstructured":"Swift, T. C. et al. Cancer at the dinner table: Experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J. Hum. Psychol. 57(5), 488\u2013519 (2017).","journal-title":"J. Hum. Psychol."},{"issue":"4","key":"53188_CR57","first-page":"354","volume":"57","author":"AB Belser","year":"2017","unstructured":"Belser, A. B. et al. Patient experiences of psilocybin-assisted psychotherapy: An interpretative phenomenological analysis. J. Hum. Psychol. 57(4), 354\u2013388 (2017).","journal-title":"J. Hum. Psychol."},{"issue":"2","key":"53188_CR58","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fphar.2018.00132","volume":"9","author":"EM Nielson","year":"2018","unstructured":"Nielson, E. M. et al. The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front. Pharmacol. 9(2), 132 (2018).","journal-title":"Front. Pharmacol."},{"issue":"10","key":"53188_CR59","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/02698811221116926","volume":"36","author":"JJ Breeksema","year":"2022","unstructured":"Breeksema, J. J. et al. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J. Psychopharmacol. 36(10), 1100\u20131117 (2022).","journal-title":"J. Psychopharmacol."},{"key":"53188_CR60","first-page":"1","volume":"9","author":"T Barba","year":"2022","unstructured":"Barba, T. et al. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open 9, 1\u201310 (2022).","journal-title":"BJPsych Open"},{"issue":"9","key":"53188_CR61","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"L Roseman","year":"2019","unstructured":"Roseman, L. et al. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. J. Psychopharmacol. 33(9), 1076\u20131087 (2019).","journal-title":"J. Psychopharmacol."},{"key":"53188_CR62","first-page":"424","volume":"44","author":"NRPW Hutten","year":"2019","unstructured":"Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. & Kuypers, K. Self-medication with psychedelic microdoses amongst microdosers with disorders. Neuropsychopharmacology 44, 424\u2013425 (2019).","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"53188_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-99269-x","volume":"12","author":"JM Rootman","year":"2022","unstructured":"Rootman, J. M. et al. Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Sci. Rep. 12(1), 1\u201310 (2022).","journal-title":"Sci. Rep."},{"key":"53188_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045125320950567","volume":"10","author":"KPC Kuypers","year":"2020","unstructured":"Kuypers, K. P. C. The therapeutic potential of microdosing psychedelics in depression. Ther. Adv. Psychopharmacol. 10, 1\u201315 (2020).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"53188_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.11.008","volume":"75","author":"T Lea","year":"2020","unstructured":"Lea, T., Amada, N., Jungaberle, H., Schecke, H. & Klein, M. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Int. J. Drug Policy 75, 102600 (2020).","journal-title":"Int. J. Drug Policy"},{"issue":"7\u20139","key":"53188_CR66","first-page":"44","volume":"19","author":"A Lyons","year":"2022","unstructured":"Lyons, A. Self-administration of psilocybin in the setting of treatment-resistant depression. Innov. Clin. Neurosci. 19(7\u20139), 44\u201347 (2022).","journal-title":"Innov. Clin. Neurosci."},{"issue":"1","key":"53188_CR67","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41598-021-81446-7","volume":"11","author":"LS Kaertner","year":"2021","unstructured":"Kaertner, L. S. et al. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci Rep. 11(1), 1941 (2021).","journal-title":"Sci Rep."},{"issue":"12","key":"53188_CR68","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1007\/s00213-022-06249-8","volume":"239","author":"I Hartogsohn","year":"2022","unstructured":"Hartogsohn, I. & Petranker, R. Set and setting in microdosing: an oft-overlooked principle. Psychopharmacology (Berlin) 239(12), 3771\u20133777 (2022).","journal-title":"Psychopharmacology (Berlin)"},{"issue":"5","key":"53188_CR69","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/01459740.2016.1160089","volume":"35","author":"C Brives","year":"2016","unstructured":"Brives, C., Le Marcis, F. & Sanabria, E. What\u2019s in a context? Tenses and tensions in evidence-based medicine. Med. Anthropol. 35(5), 369\u2013376 (2016).","journal-title":"Med. Anthropol."},{"issue":"332","key":"53188_CR70","first-page":"47","volume":"2023","author":"A Feduccia","year":"2022","unstructured":"Feduccia, A. et al. The need for establishing best practices and gold standards in psychedelic medicine. J. Affect. Disord. 2023(332), 47\u201354 (2022).","journal-title":"J. Affect. Disord."},{"issue":"326","key":"53188_CR71","first-page":"18","volume":"2023","author":"NL Modlin","year":"2022","unstructured":"Modlin, N. L. et al. Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. J. Affect. Disord. 2023(326), 18\u201325 (2022).","journal-title":"J. Affect. Disord."},{"key":"53188_CR72","first-page":"53","volume-title":"Qualitative Psychology: A Practical Guide to Methods","author":"JA Smith","year":"2007","unstructured":"Smith, J. A. & Osborn, M. Interpretative phenomenological analysis. In Qualitative Psychology: A Practical Guide to Methods (ed. Smith, J. A.) 53\u201380 (Sage, 2007)."},{"issue":"1","key":"53188_CR73","first-page":"7","volume":"20","author":"I Pietkiewicz","year":"2014","unstructured":"Pietkiewicz, I. & Smith, J. A. A practical guide to using interpretative phenomenological analysis in qualitative research psychology. Czas. Psychol. Psychol. J. 20(1), 7\u201314 (2014).","journal-title":"Czas. Psychol. Psychol. J."},{"issue":"1","key":"53188_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.17744\/mehc.38.1.04","volume":"38","author":"RM Miller","year":"2016","unstructured":"Miller, R. M. & Barrio Minton, C. A. Interpretative phenomenological analysis: A contemporary phenomenological approach. J. Ment. Health Couns. 38(1), 47\u201361 (2016).","journal-title":"J. Ment. Health Couns."},{"issue":"1","key":"53188_CR75","first-page":"39","volume":"1","author":"JA Smith","year":"2004","unstructured":"Smith, J. A. Reflecting on the development of interpretative phenomenological analysis and its contribution to qualitative research in psychology. Qual. Res. Psychol. 1(1), 39\u201354 (2004).","journal-title":"Qual. Res. Psychol."},{"issue":"2","key":"53188_CR76","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/14780887.2013.807899","volume":"11","author":"FL Engaging","year":"2014","unstructured":"Engaging, F. L. & Analysis, P. Qual. Res. Psychol. 11(2), 121\u2013141 (2014).","journal-title":"Qual. Res. Psychol."},{"issue":"6","key":"53188_CR77","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong, A., Sainsbury, P. & Craig, J. Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. Int. J. Qual. Health Care 19(6), 349\u2013357 (2007).","journal-title":"Int. J. Qual. Health Care"},{"issue":"9","key":"53188_CR78","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien, B. C., Harris, I. B., Beckman, T. J., Reed, D. A. & Cook, D. A. Standards for reporting qualitative research: A synthesis of recommendations. Acad. Med. 89(9), 1245\u20131251 (2014).","journal-title":"Acad. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53188-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53188-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53188-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T12:10:52Z","timestamp":1707135052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53188-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53188"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-53188-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RS was a co-investigator on the clinical trial on psilocybin funded by Compass Pathways. He has also received an educational grant from Janssen, Pharmaceutical Companies of Johnson and Johnson, and a honorarium from Clexio Biosciences. EV is the principal investigator of a clinical trial on MDMA funded by the Multidisciplinary Association for Psychedelic Studies. WvdB has been a consultant for Janssen Netherlands and is a member of the Scientific Advisory Board of Clearmind. JJB, AN, EK, and TK declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2929"}}